Novel Molecular Targets 2 3221 / 22 - Kevetrin i

Novel Molecular Targets 2
3221 / 22 - Kevetrin induces p53-dependent and independent cell cycle arrest and apoptosis in ovarian cancer cell lines representing heterogeneous histologies
April 4, 2017, 8:00 - 12:00 PM
________________________________________
Presenter/Authors
Ashok Kumar1, David P. Brennan1, Karima Chafai-Fadela1, Sylvia A. Holden1, Siya Ram1, Geoffrey I. Shapiro2, Krishna Menon1. 1Cellceutix Corporation, Beverly, MA; 2Dana-Farber Cancer Institute, Boston, MA
http://www.abstractsonline.com/pp8/#!/4292/presentation/3876

Some may remember a few of these names from other Kevetrin abstracts…


Kevetrin targets both MDM2-p53 and Rb-E2F pathways in tumor suppression
Ashok Kumar, Sylvia A. Holden, Karima Chafai-Fadela, Siya Ram, Krisha Menon. Cellceutix Pharmaceuticals, Beverly, MA

Abstract C49: AKT inhibitor has potent antitumor activity in human lung cancer xenograft models
Naheed Banu, Tej Hiran, K. Chafai Fadela and Krishna Menon
DOI: 10.1158/0008-5472.FBCR09-C49 Published 1 December 2009
http://cancerres.aacrjournals.org/content/69/...lement/C49


Abstract LB-283: Novel small molecule has potent antitumor activity in drug-resistant human carcinoma xenograft models
Karima Chafai-Fadela, Tej Hiran, Samantha Badger, Sylvia A. Holden, Stephen Brackett and Krishna Menon
DOI: 10.1158/1538-7445.AM10-LB-283 Published 15 April 2010
http://cancerres.aacrjournals.org/content/70/...ent/LB-283

==================================

Ashok J Kumar, M.D.
http://faculty.mdanderson.org/ashok_kumar/default.asp

=======================
David P. Brennan, Karima Chafai-Fadela
Need to find their bio’s

==========================

Sylvia A. Holden
• Director Of Research & Development
Cellceutix Corporation
April 2013 – Present (3 years 11 months)
Manage projects from pre-clinical stage to entry into clinical stage. Wrote IND for lead anti-cancer drug candidate for a Phase I clinical trial at Harvard Cancer Center and IND for lead psoriasis drug candidate for a Phase 1 clinical trial.
Manage pre-clinical pharmacology team. Design and coordinate in vivo studies, including, murine xenograft tumor models, PK studies, and in vitro studies for drug discovery. Perform data and statistical analyses, prepare research reports, and present research results.
Perform various administrative functions.

https://www.linkedin.com/in/sylviaholden

===========================

Siya Ram, Director of Chemistry, Cellceutix
On linkedin as well.


========================


GEOFFREY I. SHAPIRO, MD, PhD
DANA-FARBER CANCER INSTITUTE
EDUCATIONAL TITLES
• Associate Professor, Medicine, Harvard Medical School
• Director, Early Drug Development Center, Dana-Farber Cancer Institute
DF/HCC PROGRAM AFFILIATION
• Developmental Therapeutics, Co-Leader
• Lung Cancer, Member
DF/HCC ASSOCIATIONS
• Member, Clinical Science Coordinating Committee
Research Abstract
I conduct both basic and translational research on cyclin-dependent kinase inhibitors. A major goal is to define the role of one of these inhibitors, p16ink4a in the cellular response to DNA damage. In addition, I am directing both preclinical and clinical studies of several potent pharmacologic cyclin-dependent kinase inhibitors. Several phase I trials are underway investigating these agents in patients with advanced solid tumors. The work involves the assessment of these drugs alone, as well as in combination with standard chemotherapy agents and signal transduction inhibitors.
http://www.dfhcc.harvard.edu/insider/member-d...ro-md-phd/

===============================


Krishna Menon, PhD, DVM
Chief Scientific Officer, President of Research, and Board of Directors
Dr. Menon is a co-founder of Cellceutix, serving as Chief Scientific Officer, and Board Member. He is a leading pharmaceutical scientist with over 30 years of drug development experience in academia and industry. Prior to Cellceutix, Dr. Menon served at Eli Lilly as Group Leader, Cancer In Vivo Research and Clinical Development. While there, Dr. Menon played an integral role in lead selection and pre-clinical development of Gemzar and Alimta, two blockbuster oncology drugs. He was awarded Eli Lilly’s prestigious President’s Recognition Award. Earlier in his professional career, he held research scientist positions at Miles Laboratories and Dana Farber Cancer Research Institute. Dr. Menon is a trained veterinary surgeon (DVM) and holds a PhD (Pharmacology) from Kerala University.
http://www.cellceutix.com/board-of-directors-1/